Tattiya Kantasa

Tattiya Kantasa

Auto-generated profile, based on publicly available information

Tattiya Kantasa

Department of Pharmacology, Faculty of Medicine Chiang Mai University Chiang Mai Thailand

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
TKTattiya Kantasa
Tattiya Kantasa
KYKankanit Yeerong
Kankanit Yeerong
PKPreeyaporn Klinjan
Preeyaporn Klinjan
MTMingkwan Na Takuathung
Mingkwan Na Takuathung
KSKornvipa Settakorn
Kornvipa Settakorn
NKNut Koonrungsesomboon
Nut Koonrungsesomboon
Psoriasis is a chronic inflammatory skin disease characterized by thickened, erythematous, and scaly plaques that significantly impact patients’ quality of life. Although various treatments are available, they often cause adverse effects, prompting the exploration of alternative therapies. Curcumin, a bioactive compound in Curcuma longa Linn. (turmeric), has demonstrated potential benefits in managing psoriasis. This article aims to comprehensively evaluate the anti-psoriatic activity, efficacy, and safety profiles of curcumin and its novel formulations, as well as to discuss future directions for enhancing their use as an alternative treatment for psoriasis. Curcumin exerts its anti-psoriatic effects through multi-targeted actions, including inhibiting cell proliferation, inducing apoptosis, suppressing pro-inflammatory cytokines, and enhancing skin barrier proteins, thereby alleviating psoriasis lesions. However, both oral and topical curcumin formulations face challenges, such as low bioavailability and limited skin penetration, underscoring the need for novel formulations to improve therapeutic outcomes. Clinical findings suggest that oral curcumin may provide greater efficacy and better tolerance as an adjunctive therapy for moderate to severe psoriasis, while topical formulations may help reduce severity and improve well-being in mild to moderate cases. Overall, curcumin and its novel formulations show promise as therapeutic agents for psoriasis treatment. However, further research, particularly large-scale clinical trials, is essential to evaluate long-term efficacy and safety comprehensively.

21 January 2026 in Skin Research and Technology
Verified
Journal Article
Open access
MTMingkwan Na Takuathung
Mingkwan Na Takuathung
KYKantirat Yaja
Kantirat Yaja
JAJakkrit Aisara
Jakkrit Aisara
PKPreeyaporn Klinjan
Preeyaporn Klinjan
PAPannita Anek
Pannita Anek
NKNut Koonrungsesomboon
Nut Koonrungsesomboon
Background: With increasing life expectancy, the aging population, particularly in Asia, is expanding rapidly. Combined with intense year‐round ultraviolet exposure, this accelerates skin aging. Male skin also exhibits distinct aging characteristics. This study aims to evaluate the efficacy and safety of the Genistein Plus Bakuchiol and Vitamins (GEN + ) product on male facial skin. Materials and Methods: A randomized, double‐blind, placebo‐controlled trial was conducted in men aged 45–65 years. Participants were assigned to receive either the GEN + or placebo (PLA) product in a 1:1 ratio and applied the product twice daily for 12 weeks. Facial skin assessments were performed at baseline and at weeks 4, 8, and 12. Evaluated parameters included skin color and consistency, spots, pigmentation, redness, acne, elasticity, hydration, barrier function, and wrinkles. Compliance and satisfaction were also monitored. Results: Eighty male participants were enrolled (GEN + : n = 40; PLA: n = 40). After 12 weeks, the GEN + group demonstrated significant improvements in cheek skin lightening (MD = 0.55, 95% CI: 0.03 to 1.08, p = 0.04) and color consistency (MD = –0.56, 95% CI: –1.06 to –0.06, p = 0.03), along with a reduction in forehead spots (MD = –0.60, 95% CI: –1.15 to –0.06, p = 0.03). No significant differences were observed in melanin‐, erythema‐, or acne‐related parameters. Skin property parameters did not differ significantly between groups, except for skin roughness. Adverse events were mild and self‐resolving. While satisfaction scores did not differ significantly, the GEN + group reported higher scores across most domains. Conclusion: The GEN + product demonstrated promising improvements in male facial skin appearance, including skin lightening, color consistency, and spot reduction. The product was well‐tolerated and offered a safe, targeted skincare solution for men. Trial Registration: ClinicalTrials.gov identifier: TCTR20240312001